Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine XR vs Lithium in Treatment Resistant Depression
NCT00789854Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of quetiapine in major depressive disorder (MDD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in Montgomery-Åsberg Depression Rating Scale Total Score at 6 weeks. Started Nov 2008; status: completed.
02
Drugs
quetiapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00789854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00789854.